ImmuPharma plc (LON:IMM – Get Free Report)’s stock price was up 27% on Friday . The stock traded as high as GBX 3.60 ($0.04) and last traded at GBX 3.60 ($0.04). Approximately 5,919,609 shares changed hands during mid-day trading, a decline of 69% from the average daily volume of 18,940,990 shares. The stock had previously closed at GBX 2.84 ($0.04).
ImmuPharma Stock Performance
The firm’s 50 day moving average price is GBX 1.71 and its two-hundred day moving average price is GBX 1.72. The firm has a market cap of £16.05 million, a PE ratio of -385.50 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Featured Stories
- Five stocks we like better than ImmuPharma
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Market Momentum: 3 Stocks Poised for Significant Breakouts
- What Are Dividend Challengers?
- Kinder Morgan’s Uptrend is Only Half Over: New Highs Are Coming
- Conference Calls and Individual Investors
- Momentum Builders: 3 Stocks Positioned to Shine This Quarter
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
